Advanced Glycation Endproduct-BSA

Description

• General description: Prepared by reacting BSA with glycoaldehyde under sterile conditions. Glycated-BSA shows a 5,000 - 10,000% increase in fluorescence as compared to normal BSA (confirmed by fluorescence spectrophotometry, excitation/emission 370/440 nm). AGE-BSA has been reported to induce apoptosis in cultured human umbilical vein endothelial cells and inhibit nitric oxide synthase activity in proximal tubular epithelial cells. Advanced glycation end products and their receptors have been implicated in the pathogenesis of diabetes, induction of proinflammatory cytokines, and stimulation of smooth muscle proliferation, and fibronectin production.
• Warning: Toxicity: Standard Handling (A)
• Physical form: In sterile-filtered PBS.
• Other Notes: Okamoto, T., et al. 2002. Microvasc. Res.63, 186.Ohgami, N., et al. 2001. J. Biol. Chem.276, 3195.Wang, R., et al. 2001. J. Nippon Med. Sch.68, 472.Sakata, N., et al. 2000. J. Atheroscler. Thromb.7, 169.Verbeke, P., et al. 2000. Biochim. Biophys. Acta1502, 481.Farboud, B., et al. 1999. Mol. Vis.5, 11.Huang, J.-S., et al. 1999. Biochem. J.342, 231.Min, C., et al. 1999. Diabetes Res. Clin. Pract.46, 197.Neumann, A., et al. 1999. FEBS Lett.453, 283.Stitt, A.W., et al. 1999. Biochem. Biophys. Res. Commun.256, 549.Nazaimoon, W. and Bak, K. 1998. Malays. J. Pathol.20, 83.
• Legal Information: CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany